The first quarter of the new financial year saw Sawai Pharmaceutical Co., Ltd.’s outlook improve, but National Health Insurance drug price revisions continue to take a toll on Japan’s generics industry with uncertainty surrounding any forthcoming reform.
Steady growth was made across the business in line with forecasts, with sales up 11.5% year-on-year in Japan to ¥43.2bn...






